Pfizer (PFE) Capital Expenditures (2009 - 2026)

Pfizer (PFE) has reported Capital Expenditures for 18 consecutive years, with $533.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 13.75% year-over-year to $533.0 million in Q2 2026; TTM through Jun 2026 was $2.4 billion, a 36.6% decrease from a year earlier, with the FY2025 full-year figure at $2.6 billion, down 9.63% from the prior year.
• Capital Expenditures was $533.0 million for Q2 2026 at Pfizer, up from $436.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.0 billion in Q3 2024 and troughed at $436.0 million in Q1 2026.
• A 5-year average of $815.9 million and a median of $673.5 million in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 77.14% in 2023 and plunged 69.78% in 2025, its largest moves.
• Over 5 years, Capital Expenditures stood at $751.0 million in 2022, then surged by 39.01% to $1.0 billion in 2023, then jumped by 90.8% to $2.0 billion in 2024, then plunged by 57.58% to $845.0 million in 2025, then tumbled by 36.92% to $533.0 million in 2026.
• The last three Capital Expenditures figures came in at $533.0 million (Q2 2026), $436.0 million (Q1 2026), and $845.0 million (Q4 2025), per Business Quant data.